CD44 and renal carcinoma: HuRCSCs, identified by the CD44+/CD105+ markers, were found to exhibit significantly higher levels of both genomic 5hmC and TET1 expression compared to non-stem renal cancer cells (HuNRCCs, CD44-/CD105-).